Orelabrutinib could be ‘preferred’ BTK inhibitor for MCL
ORLANDO – Orelabrutinib produced an 86% response rate in a phase 2 trial and appears to be safer than ibrutinib.
Related Articles
Bronchiectasis: A call to action
The nonCF bronchiectasis community has been trying to organize to provide better care for patients in the US.
New developments on the forefront of intermediate-risk pulmonary embolism
While systemic anticoagulation is the mainstay therapy, select individuals may benefit from more immediate reperfusion.
Hospital to home tracheostomy care
Caregivers need to be educated on daily tracheostomy care, airway clearance, and ventilator management.
HALT early recognition is key
HALT manifests as elevated serum ammonia levels with symptoms ranging from encephalopathy to seizures and cerebral edema.
Advancements in nutritional management for critically ill patients
Nutrition plays an important role in the management and recovery of critically ill patients admitted to the ICU.
Top reads from the CHEST journal portfolio
Editorial board memebers share their picks of top journal articles in recent months.
The countdown to CHEST 2024 begins
Every year is different, with the culture of the location guiding the way and new opportunities to network while engaging in activity..
OSA in pregnancy: Who to test, how to screen, and does treatment help?
OSA in pregnancy is associated with hypertensive disorders of pregnancy, gestational diabetes, preterm birth, etc.
The language of AI and its applications in health care
AI can make clinical care more efficient; however, many find its confusing terminology to be a barrier.
Trauma epidemiology and the organization of trauma care in the US
Patients who are injured do better when treated at trauma centers.